THOMAS R PORTER, MD
Osteopathic Medicine at Nebraska Medical Ctr, Omaha, NE
License number
Nebraska 18875
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
988102 Nebraska Medical Ctr, Omaha, NE 68198
Phone
(402) 559-8888
(402) 559-3060 (Fax)
(402) 559-3060 (Fax)
Organization information
See more information about THOMAS R PORTER at bizstanding.comUnmc Physicians Heart Center - Thomas R Porter DDS
4400 Emile St, Omaha, NE 68198
Categories:
Dentists
Site:
Phone:
(402) 559-8888 (Phone)
Professional information
Thrombolytic Agents And Methods Of Treatment For Thrombosis
US Patent:
6197345, Mar 6, 2001
Filed:
Nov 8, 1999
Appl. No.:
9/435050
Inventors:
Thomas R. Porter - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A61K 950
US Classification:
424490
Abstract:
The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
Thrombolytic Agents And Methods Of Treatment For Thrombosis
US Patent:
2001000, Jul 19, 2001
Filed:
Jan 11, 2001
Appl. No.:
09/758799
Inventors:
Thomas Porter - Omaha NE, US
International Classification:
A61K038/00, A61K031/70, A61K009/16, A61K009/50
US Classification:
514/021000, 514/023000, 424/490000
Abstract:
The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
Thrombolytic Agents And Methods Of Treatment For Thrombosis
US Patent:
5980950, Nov 9, 1999
Filed:
Apr 3, 1997
Appl. No.:
8/832532
Inventors:
Thomas R. Porter - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A61K 950
US Classification:
424490
Abstract:
The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
Thrombolytic Agents And Methods Of Treatment For Thrombosis
US Patent:
5648098, Jul 15, 1997
Filed:
Oct 17, 1995
Appl. No.:
8/544204
Inventors:
Thomas R. Porter - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A61K 950, A61B 800
US Classification:
424490
Abstract:
The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
Suspended Ultra-Sound Induced Microbubble Cavitation Imaging
US Patent:
5740807, Apr 21, 1998
Filed:
Sep 26, 1996
Appl. No.:
8/721507
Inventors:
Thomas R. Porter - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A61B 800
US Classification:
12866202
Abstract:
An ultrasonic imaging technique is disclosed which uses microbubbles as echo contrast agents. In general the method employs maitenance of an ultrasound signal while the contrast agent is intravenously injected into a mammal. Once all the contrast agent has been injected and transmission of the signal is suspended for a period of time sufficient for the microbubbles perfuse the organ of interest. Transmission of the ultrasound signal is then resumed and peak contrast images are obtained which rival more complicated imaging procedures such as nuclear resonance imaging.
Suspended Ultra-Sound Induced Microbubble Cavitation Imaging
US Patent:
5560364, Oct 1, 1996
Filed:
May 12, 1995
Appl. No.:
8/439619
Inventors:
Thomas R. Porter - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A61B 800
US Classification:
12866202
Abstract:
An ultrasonic imaging technique is disclosed which uses microbubbles as echo contrast agents. In general the method employs maitenance of an ultrasound signal while the contrast agent is intravenously injected into a mammal. Once all the contrast agent has been injected and transmission of the signal is suspended for a period of time sufficient for the microbubbles perfuse the organ of interest. Transmission of the ultrasound signal is then resumed and peak contrast images are obtained which rival more complicated imaging procedures such as nuclear resonance imaging.
Compositions And Methods For Altering The Biodistribution Of Biological Agents
US Patent:
7198949, Apr 3, 2007
Filed:
Sep 22, 2003
Appl. No.:
10/668448
Inventors:
Thomas R. Porter - Omaha NE, US
Patrick L. Iversen - Corvallis OR, US
Patrick L. Iversen - Corvallis OR, US
Assignee:
Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
C12N 15/63, C12Q 1/68, C12P 19/34, C07K 1/00, C07H 21/04
US Classification:
435455, 435 6, 435 911, 435 917, 530300, 530350, 530362, 536 231, 536 245
Abstract:
The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
Microbubble Compositions And Methods For Oligonucleotide Delivery
US Patent:
7115583, Oct 3, 2006
Filed:
Jan 31, 2003
Appl. No.:
10/355388
Inventors:
Thomas R. Porter - Omaha NE, US
Patrick L. Iversen - Corvallis OR, US
Patrick L. Iversen - Corvallis OR, US
Assignee:
AVI Biopharma, Inc. - Corvallis OR
International Classification:
A01N 37/18, A01N 43/04, C07K 1/00, C07H 21/02, C12P 19/34
US Classification:
514 44, 424 952, 435 6, 435 911, 514 1, 514 2, 530350, 530362, 530363, 530380, 536 231, 536 245
Abstract:
The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.
Suspended Ultra-Sound Microbubble Imaging
US Patent:
5685310, Nov 11, 1997
Filed:
Oct 10, 1995
Appl. No.:
8/540463
Inventors:
Thomas R. Porter - Omaha NE
Assignee:
The Board of Regents of the University of Nebraska - Lincoln NE
International Classification:
A61B 800
US Classification:
12866202
Abstract:
An ultrasonic imaging technique is disclosed which uses microbubbles as echo contrast agents. In general the method employs maintenance of an ultrasound signal while the contrast agent is intravenously injected into a mammal. Once all the contrast agent has been injected and transmission of the signal is suspended for a period of time sufficient for the microbubbles perfuse the organ of interest. Transmission of the ultrasound signal is then resumed and peak contrast images are obtained which rival more complicated imaging procedures such as nuclear resonance imaging.
Detection Of Endothelial Dysfunction By Ultrasonic Imaging
US Patent:
7025726, Apr 11, 2006
Filed:
Jan 22, 2004
Appl. No.:
10/764294
Inventors:
Thomas R. Porter - Omaha NE, US
Feng Xie - Omaha NE, US
Feng Xie - Omaha NE, US
Assignee:
The Regents of the University of Nebraska - Lincoln NE
International Classification:
A61B 8/06
US Classification:
600458
Abstract:
A method for non-invasive detection of vascular endothelial dysfunction using ultrasonic imaging is provided.